{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fenfluramine+Hydrochloride",
    "query": {
      "intervention": "Fenfluramine Hydrochloride"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 20,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fenfluramine+Hydrochloride&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T00:44:36.866Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03936777",
      "title": "A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome",
        "Lennox Gastaut Syndrome",
        "Epileptic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 412,
      "start_date": "2019-04-22",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 26,
      "location_summary": "Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936777"
    },
    {
      "nct_id": "NCT03467113",
      "title": "A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dravet Syndrome",
        "Lennox Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "ZX008 0.2 to 0.8 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Cannabidiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 9,
      "start_date": "2018-01-19",
      "completion_date": "2020-06-24",
      "has_results": false,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Tacoma, Washington",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03467113"
    },
    {
      "nct_id": "NCT07112365",
      "title": "The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "Fenfluramine treatment (Fintepla)",
          "type": "DRUG"
        },
        {
          "name": "Hypercapnia Challenge using the device (RespirAct)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-04-27",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07112365"
    },
    {
      "nct_id": "NCT04437004",
      "title": "Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "Fenfluramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04437004"
    },
    {
      "nct_id": "NCT04289467",
      "title": "Treatment of Refractory Infantile Spasms With Fenfluramine",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infantile Spasm"
      ],
      "interventions": [
        {
          "name": "Fenfluramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital of Orange County",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "12 Months to 36 Months"
      },
      "enrollment_count": 10,
      "start_date": "2023-06-16",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Orange, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04289467"
    },
    {
      "nct_id": "NCT03861871",
      "title": "Fenfluramine in CDKL5 Deficiency Disorder (CDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CDD"
      ],
      "interventions": [
        {
          "name": "Fenfluramine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-10-29",
      "completion_date": "2022-10-24",
      "has_results": true,
      "last_update_posted_date": "2023-10-04",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03861871"
    },
    {
      "nct_id": "NCT02682927",
      "title": "A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome",
        "Seizure Disorder"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 262,
      "start_date": "2016-01-15",
      "completion_date": "2020-07-29",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682927"
    },
    {
      "nct_id": "NCT00000313",
      "title": "Predictive Values of Serotonergic Alterations for Outcome - 2",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Fenfluramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "25 Years to 50 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000313"
    },
    {
      "nct_id": "NCT05064878",
      "title": "A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "CDKL5 Deficiency Disorder",
        "Generalized Tonic Clonic Seizure",
        "Epileptic Spasm",
        "Refractory Seizures"
      ],
      "interventions": [
        {
          "name": "Fenfluramine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "1 Year to 35 Years"
      },
      "enrollment_count": 87,
      "start_date": "2022-03-08",
      "completion_date": "2027-11-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05064878"
    },
    {
      "nct_id": "NCT03790137",
      "title": "Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Photosensitive Epilepsy"
      ],
      "interventions": [
        {
          "name": "Fenfluramine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elizabeth Anne Thiele",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 20,
      "start_date": "2019-05-31",
      "completion_date": "2024-07-19",
      "has_results": true,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-09-23T00:44:36.866Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03790137"
    }
  ]
}